Promising results of Providence-sponsored trial published in npj Breast Cancer

Monday, July 3, 2023

The final outcomes from a Providence Cancer Institute-sponsored phase Ib trial were published in npj Breast Cancer on June 21. The trial evaluated pembrolizumab, an immunotherapy, with either weekly paclitaxel or flat-dose capecitabine in treating patients with metastatic triple-negative breast cancer. Both regimens achieved predetermined safety and efficacy outcomes. The study, “A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer,” was led by David B. Page, M.D., Providence Cancer Institute. npj Breast Cancer is an open access, multidisciplinary research journal dedicated to publishing leading-edge breast cancer research and treatment.  

Read about the trial.  

Related news

Providence researchers contribute to more than 20 studies presented at ASCO Annual Meeting

Breast cancer survivor, artist gives back to Providence

Providence Willamette Falls celebrates opening of new cancer center

Celebrating World Immunology Day
4/26/2024
Providence Cancer Institute researcher shares her journey to immunology and the advice she has for those seeking a career in cancer research.
New vaccine being studied for HPV-positive head and neck cancers
4/17/2024
Researchers at Providence Cancer Institute are exploring a range of innovative approaches to targeting human papillomavirus-positive head and neck squamous cell cancer.
Looking ahead: Growth and advancements in surgical oncology at Providence Cancer Institute
4/3/2024
Growing the surgical oncology programs at Providence Cancer Institute is a testament to our commitment to providing research-focused, comprehensive services and improving outcomes for patients.
Celebrating our oncology social workers
3/25/2024
In recognition of National Social Work Month, Darlene Corral, LCSW, shares a little insight into the importance of oncology social workers.